Q32 Bio Holds $289.6 Million In Cash, Enough To Reach Phase 3 Alopecia Results

The alopecia drug developer plans regulator talks this quarter ahead of a late-stage bempikibart program in the first half of 2027.

Share
Q32 Bio Holds $289.6 Million In Cash, Enough To Reach Phase 3 Alopecia Results

Q32 Bio, which develops biologic drugs for alopecia areata, an autoimmune condition that causes hair loss, said in an 8-K filed Wednesday that its $289.6 million in cash at September 30, 2026 should fund operations through topline results from a planned Phase 3 program. The company reported a third-quarter net loss of $8.9 million, or $0.26 per share.

A $200 million raise rebuilt the balance sheet

Cash stood at $289.6 million on September 30, against $48.3 million at December 31, 2025. In July 2026 the company completed a public offering of common stock and pre-funded warrants that brought in gross proceeds of about $200.0 million, before underwriting discounts, commissions and expenses.

Venture debt, which stood at $9.7 million at the end of 2025, no longer appears on the balance sheet. Stockholders' equity was $287.7 million, up from $42.0 million.

The net loss of $8.9 million compares with $7.4 million, or $0.60 per share, a year earlier. The per-share loss narrowed because the weighted-average share count rose to about 34.0 million from about 12.2 million.

Research and development spending rose to $5.1 million from $3.6 million, on higher bempikibart clinical and manufacturing costs and preclinical work on ADX-914-XL. General and administrative costs reached $5.5 million from $4.0 million, mainly on stock-based compensation and other employee costs.

Bempikibart data and the path to Phase 3

Bempikibart is an antibody that blocks the IL-7 and TSLP immune signals. In Part B of the Phase 2a SIGNAL-AA trial, which enrolled 33 patients with severe or very severe alopecia areata, the mean reduction in hair-loss severity score at Week 36 was 35.3% in the modified intent-to-treat analysis. A SALT-20 response, meaning 80% scalp hair coverage, came in at 40.0% of patients in that analysis and 30.3% in the analysis of all enrolled patients.

The company said responses were maintained or deepened through a 16-week off-drug period, and that the drug was generally well tolerated with no new safety signals. The data were presented at the EADV Congress in September.

CEO Jodie Morrison said the data show "the potential for bempikibart to become a first-line standard of care option for patients with alopecia areata." That is the company's belief, not a trial finding.

Regulator talks this quarter

Q32 Bio plans regulatory discussions in the fourth quarter of 2026. It expects to start a registration-directed program in severe or very severe alopecia areata in the first half of 2027, subject to those talks.

Data from the ongoing open-label extension are expected in the second half of 2027. In September the company named José Trevejo as chief medical officer and Ellie Hershberger as chief development officer to lead late-stage development.

The next marker is the fourth-quarter regulatory discussions that gate the planned first-half 2027 start of the registration-directed program.

Sources

More on Q32 Bio

All Q32 Bio (QTTB) coverage →